Steve Brozak
Stock Analyst at WBB Securities
(1.06)
# 3,788
Out of 5,050 analysts
14
Total ratings
28.57%
Success rate
-3.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $6.59 | +582.85% | 3 | Oct 15, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Strong Buy | $123 → $199 | $104.39 | +90.63% | 5 | Oct 9, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.78 | +237.08% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $0.86 | +1,345.25% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.14 | +1,403,408.77% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $6.59
Upside: +582.85%
Cidara Therapeutics
Oct 9, 2025
Maintains: Strong Buy
Price Target: $123 → $199
Current: $104.39
Upside: +90.63%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.78
Upside: +237.08%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $0.86
Upside: +1,345.25%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.14
Upside: +1,403,408.77%